welcome
Insider Trading & Hedge Fund Data, and Investment Newsletter From Insider Monkey

Insider Trading & Hedge Fund Data, and Investment Newsletter From Insider Monkey

Business

Business & Economics

Medtronic Stock Rated Outperform as Renal Denervation and Spin-Off Drive Growth Potential

Insider Trading & Hedge Fund Data, and Investment Newsletter From Insider Monkey
Summary
Nutrition label

79% Informative

RBC Capital reiterated a $ 101 price target and an Outperform rating on Medtronic, Inc. ( NYSE :MDT) on June 18 .

The firm assessed the potential of the company’s Symplicity Spyral renal denervation system, which treats hypertension, using a private survey with forty-four respondents.

The survey results will be made public in advance of the crucial Centers for Medicare & Medicaid Services ( CMS ) National Coverage Determination , which is scheduled for July 11, 2025 .

VR Score

79

Informative language

80

Neutral language

2

Article tone

formal

Language

English

Language complexity

69

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

medium-lived

Source diversity

1

Affiliate links

no affiliate links